TY - JOUR
T1 - Atypical antipsychotic use during pregnancy and birth defect risk
T2 - National Birth Defects Prevention Study, 1997–2011
AU - the National Birth Defects Prevention Study
AU - Anderson, Kayla N.
AU - Ailes, Elizabeth C.
AU - Lind, Jennifer N.
AU - Broussard, Cheryl S.
AU - Bitsko, Rebecca H.
AU - Friedman, Jan M.
AU - Bobo, William V.
AU - Reefhuis, Jennita
AU - Tinker, Sarah C.
N1 - Funding Information:
This project was supported through Centers for Disease Control and Prevention (CDC) cooperative agreements under PA # 96043 , PA # 02081 , and FOA # DD09-001 , and NOFO # DD18-001 to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study (NBDPS) and/or the Birth Defects Study to Evaluate Pregnancy ExposureS (BD-STEPS). William V. Bobo's research has been supported by grants from the National Institute of Mental Health , Agency for Healthcare Research and Quality , and the Mayo Foundation for Medical Education and Research .
Funding Information:
This project was supported through Centers for Disease Control and Prevention (CDC) cooperative agreements under PA #96043, PA #02081, and FOA #DD09-001, and NOFO #DD18-001 to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study (NBDPS) and/or the Birth Defects Study to Evaluate Pregnancy ExposureS (BD-STEPS). William V. Bobo's research has been supported by grants from the National Institute of Mental Health, Agency for Healthcare Research and Quality, and the Mayo Foundation for Medical Education and Research.
Publisher Copyright:
© 2019
PY - 2020/1
Y1 - 2020/1
N2 - Purpose: To examine the prevalence of, and factors associated with, atypical antipsychotic use among U.S. pregnant women, and potential associations between early pregnancy atypical antipsychotic use and risk for 14 birth defects. Methods: We analyzed data from the National Birth Defects Prevention Study (1997–2011), a U.S. population-based case-control study examining risk factors for major structural birth defects. Results: Atypical antipsychotic use during pregnancy was more common among women with pre-pregnancy obesity, and women who reported illicit drug use before and during pregnancy, smoking during pregnancy, alcohol use during pregnancy, or use of other psychiatric medications during pregnancy. We observed elevated associations (defined as a crude odds ratio [cOR] ≥2.0) between early pregnancy atypical antipsychotic use and conotruncal heart defects (6 exposed cases; cOR: 2.3, 95% confidence interval [CI]: 0.9–6.1), and more specifically Tetralogy of Fallot (3 exposed cases; cOR: 2.5, 95% CI: 0.7–8.8), cleft palate (4 exposed cases, cOR: 2.5, 95% CI: 0.8–7.6), anorectal atresia/stenosis (3 exposed cases, cOR: 2.8, 95% CI: 0.8–9.9), and gastroschisis (3 exposed cases, cOR: 2.1, 95% CI: 0.6–7.3). Conclusions: Our findings support the close clinical monitoring of pregnant women using atypical antipsychotics. Women treated with atypical antipsychotics generally access healthcare services before pregnancy; efforts to reduce correlates of atypical antipsychotic use might improve maternal and infant health in this population.
AB - Purpose: To examine the prevalence of, and factors associated with, atypical antipsychotic use among U.S. pregnant women, and potential associations between early pregnancy atypical antipsychotic use and risk for 14 birth defects. Methods: We analyzed data from the National Birth Defects Prevention Study (1997–2011), a U.S. population-based case-control study examining risk factors for major structural birth defects. Results: Atypical antipsychotic use during pregnancy was more common among women with pre-pregnancy obesity, and women who reported illicit drug use before and during pregnancy, smoking during pregnancy, alcohol use during pregnancy, or use of other psychiatric medications during pregnancy. We observed elevated associations (defined as a crude odds ratio [cOR] ≥2.0) between early pregnancy atypical antipsychotic use and conotruncal heart defects (6 exposed cases; cOR: 2.3, 95% confidence interval [CI]: 0.9–6.1), and more specifically Tetralogy of Fallot (3 exposed cases; cOR: 2.5, 95% CI: 0.7–8.8), cleft palate (4 exposed cases, cOR: 2.5, 95% CI: 0.8–7.6), anorectal atresia/stenosis (3 exposed cases, cOR: 2.8, 95% CI: 0.8–9.9), and gastroschisis (3 exposed cases, cOR: 2.1, 95% CI: 0.6–7.3). Conclusions: Our findings support the close clinical monitoring of pregnant women using atypical antipsychotics. Women treated with atypical antipsychotics generally access healthcare services before pregnancy; efforts to reduce correlates of atypical antipsychotic use might improve maternal and infant health in this population.
KW - Antipsychotics
KW - Birth defects
KW - Mental health
KW - Pharmacoepidemiology
UR - http://www.scopus.com/inward/record.url?scp=85076234326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076234326&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2019.11.019
DO - 10.1016/j.schres.2019.11.019
M3 - Article
C2 - 31761471
AN - SCOPUS:85076234326
SN - 0920-9964
VL - 215
SP - 81
EP - 88
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -